TCM
GILD icon

Tetrem Capital Management’s Gilead Sciences GILD Stock Holding History

Tetrem Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-479,814
Closed -$32.6M – 59
2017
Q1 		$32.6M Buy
479,814
+83,512
+21% +$5.87M 1.34% 41
2016
Q4 		$28.4M Sell
396,302
-16,471
-4% -$1.22M 1.14% 44
2016
Q3 		$32.7M Buy
+412,773
New +$33.5M 1.23% 41

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tetrem Capital Management's GILD Position: Q2 2017 in Review

Tetrem Capital Management sold out of Gilead Sciences (GILD) in Q2 2017, closing a stake of 479,814 shares — an estimated $32.6M sold.

Tetrem Capital Management first reported a position in GILD in Q3 2016 and held it in 3 quarters. The position peaked at $32.7M in Q3 2016. 1,519 funds tracked by Wall St. Rank hold GILD as of Q2 2017.

  • Tetrem Capital Management reported no remaining Gilead Sciences position as of Q2 2017 after selling out during the quarter.
  • Tetrem Capital Management sold 479,814 Gilead Sciences shares in Q2 2017, an estimated $32.6M.
  • Tetrem Capital Management first reported a position in Gilead Sciences in Q3 2016 and held it in 3 quarters.
  • Tetrem Capital Management's Gilead Sciences position peaked at $32.7M in Q3 2016.
  • 1,519 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2017.

Based on Tetrem Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.